Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tocilizumab in MOGAD
NCT06452537Phase 3Active, not recruiting
- Sponsor
- Tianjin Medical University General Hospital
- Start
- Jul 2024
- Primary completion
- Jan 2026
- Modality
- Antibody Conjugates, Recombinant Proteins and Enzymes, Engineered Antibody Formats
- Countries
- 1
01
Overview
A Phase 3 trial of tocilizumab in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), sponsored by Tianjin Medical University General Hospital. Started Jul 2024; status: active, not recruiting.
02
Drugs
tocilizumab
03
Conditions
myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD)
Beyond the preview
Go deeper on NCT06452537.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06452537.